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Cholinergie agents arepotent modulators of insulin release that aet via musearinie reeeptors. We now investigated 
the musearlnie receptor subtype present in rat panereatic islets in binding and funetional studies. Binding of 5 nM 
[ 3 H]N-methylscopolamine ([ 3H]NMS) was half maximal at 30 min. At 60 min, the maximal total bindingwas 1.29% 
and the non-specifie binding (presence of 100 ,uM atropine) was 0.18% of the total radioaetivity per 10 f.'g islet protein. 
Unlabelled atropine inhibited [3H]NMS binding with an IC50 of ca. 30 nM. The rank order of antagonist high-affinity 
binding was atropine > sila-hexocyelium methyl sulfate (SiHC; M1 > M 3 > M2 ) > pirenzepine (MI> M 2 = M 3 ) = 
methoctramine (M 2 > M1 > M 3 ). The high-affinity Kds were 8.5, 56, 1300 and 1300 nM, respectively. The high 
affinity Kd of the muscarinie receptor agonist, arecaidine propargyl ester (APE), was 8.1 nM. The EC50 for the 
biologieal effects of APE on insulin and glucagon secretion was 3.2 and 2.3 nM. The rank order for the high-affinity 
biological effects of antagonists (inhibition of APE-mediated insulin/ glucagon release) was almost the same as for 
binding. The data indicate that rat pancreatie islets contain neither an MI subtype (high-affinity for pirenzepine) nor 
an M 2 subtype (high-affinity for methoctramine) receptor. However, the data evidence an M3 receptor subtype, since 
SiHC in the absence of the M1 receptor subtype shows a relatively high affinity to the receptors in rat panereatie islets. 
Muscarinic receptor subtypes; Islets of Langerhans (rat); Insulin; Glucagon 
1. Introduction 
The pancreatic islets of Langerhans are in-
nervated by parasympathetic nervous fibres 
(Coupland, 1958) which are organized in a perlin-
sular plexus with direct innervation to the cells 
(Miller, 1981). Cholinergic Stimulation of insulin 
release is thought to participate in the secretory 
response of the pancreatic B-cell to food intake, 
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e.g. in the cephalic phase of insulin secretion 
(Malaisse, 1972). The importance of cholinergic 
innervation for islet function is suggested by the 
10-fold higher concentration of choline acetyl-
transferase in the islets versus that in the adjacent 
exocrine tissue (Godfrey and Matschinsky, 1975). 
In vivo and in vitro administration of musearlnie 
agonists stimulates insulin secretion (Malaisse, 
1972). The stimulatory action of acetylcholine on 
the endocrine pancreas is abolished by atropine 
(Grill and Östenson, 1983; Kaneto and Kosaka, 
1974; Holst et al., 1981; Honey and Weir, 1980); 
the IC50 for .inhibition of acetylcholine-induced 
insulin release by the antagonist methylscopola-
mine is less than 0.4 nM (Grill and Östenson, 
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1983). Binding studies with [ 3H]N-methyl-
scopo1amine (eHJNMS) (Malaisse et al., 1985) or 
[ 3H]quinuclidinylbenzilate (Palafox et al., 1986) 
demonstrated the presence of muscarinic receptors 
in islets. The IC50 of inhibition of [3H]NMS bind-
ing in rat pancreatic islets was approximately 5 
nM when unlabelled N-methylscopolamine was 
used (Östenson and Grill, 1985). 
At least three different muscarinic receptor 
subtypes have been proposed on the basis of dif-
ferent affinities for antagonists such as pirenze-
pine (Hammer and Giachetti, 1982), methoctra-
mine (Melchiorre, 1988; Melchiorre et al., 1987), 
AF-DX 116 (Micheletti et al., 1987) and bexa-
hydro-sila-difenidol as weil as sila-hexocyclium 
(SiHC; Lambrecht et al., 1988; Eltze et al., 1988; 
Waelbroeck et al., in press). The subtypes have 
been termed M1 (neuronal type), M 2 (M 2a; cardiac 
type) and M3 (M2p smooth musclejglandular 
type) receptors (for recent reviews see Mitchelson, 
1988; Melchiorre, 1988; Mutschier et al., 1988). 
Five receptor subtypes were identified by molecu-
lar cloning studies and were found to be the 
products of distinct genes. These subtypes were 
termed m1 to m5 (Bonner et al., 1987; Buckley et 
al., in press). The antagonist binding properties of 
the individual cloned m1, m2 and m3 receptors 
and their pattems of expression in various tissues 
correspond closely to those of the pharmacologi-
cally defined M1, M 2 and M 3 receptors (Peralta et 
al., 1987; Akiba et al., 1988; Maeda et al., 1988; 
Buckley et al., in press). 
The limited selectivity of available ligands has 
long hampered receptor subtype characterization 
in pancreatic islets. The results of functional sturl-
ies ruled out the presence of M 2 cardiac type 
receptors in mouse islets (Henquin and Nenquin, 
1988) as weil as that of the M1 subtype in rat 
endocrine pancreas (Otsuki et al., 1985). In the 
present study an attempt was made to characterize 
the muscarinic receptor subtype in both functional 
and binding studies with rat islets of Langerhans. 
Pirenzepine (M1 > M 2 = M 3 ) (Hammer et al., 
1980}, methoctramine (M 2 > M1 > M 3 ) (Melchi-
orre et al., 1987; Melchiorre, 1988), and SiHC 
(M 1 > M 3 > M 2 ) (Lambrecht et al., 1987; 
Waelbroeck et al., 1989) were used for the pur-
pose. 
2. Materials and methods 
2.1. Animals 
Wistar rats of either sex, weighing between 180 
and 250 g, were used. They were kept on a stan-
dard pellet diet (Altromin, LagejLippe, W. 
Germany) and tap water ad libitum at 22 ° C with 
a 12-h lightjdark rhythm. 
2. 2. Drugs and chemieals 
The following compounds were purchased or 
synthesized: atropine nitrate from Merck (Darm-
stadt, W. Germany), arecaidine propargyl ester 
(APE) (Mutschler and Hultzsch, 1973) and sila-
hexocyclium (SiHC) (Tacke et al., 1989) synthe-
sized in one of our laboratories. Pirenzepine dihy-
drochloride was from Boehringer lngelheim (ln-
gelheim, FRG) and methoctramine (N,N'-bis[6-
(2-methoxybenzyl)aminohexyl]-1 ,8-octanediamine) 
tetrahydrochloride was kindly provided by Dr. 
Carlo Melchiorre, University of Bologna (ltaly). 
[ 3H]N-methylscopolarnine [3H]NMS; 72 Cij 
mmol = 2664 GBqjmrnol) was from Amersham 
Buchler (Braunschweig, W. Germany); pilocarpine 
hydrochloride, soybean trypsin inhibitor (SBTI), 
bacitracin and HEPES from Sigma Chemical Co. 
(St. Louis, MO); bovine serum albumin (BSA) 
fraction V from Miles Laboratories (Elkart, IN); 
collagenase (CLS grade) from Worthington Bio-
chemieals Corp. (Freehold, NJ). Insulin radioim-
munoassay kits were supplied by Isotopendienst 
West, GmbH (Dreieich, W. Germany). Ratinsulin 
was purchased from the Novo Research Institute 
(Copenhagen, Denmark). The glucagon kit includ-
ing glucagon standards was from Serono (Frei-
burg, W. Germany). 
2.3. Isolation of rat pancreatic islets 
The procedure for isolation of pancreatic islets 
was the one described by Lacy and Kostianovsky 
(1967) with slight modifications as described earlier 
(Verspohl and Ammon, 1980). Three rats were 
pretreated with 0.3 ml of 4% pilocarpine hydro-
chloride i.p. The animals were killed with ether 
after 3 h and the pancreases were isolated, minced, 
and washed twice with 20 ml ice-cold Hanks solu-
tion containing 3.7 mM glucose, 1 mgjml 
bacitracin, 0.2 mgjml SBTI and 0.2% albumin. 
Pancreas pieces were soaked and shaken in a 
water bath at 37 ° C in the presence of 650 U 
collagenasejg tissue suspension. After 15-18 min 
of incubation the tissue suspension was passed 
into 10 ml of ice-cold Hanks solution. The islets 
were separated by sedimentation and collected as 
described elsewhere (Lacy and Kostianovsky, 
1967). This method yields 300-500 isletsjrat pan-
creas. The islets were carefully selected in order to 
avoid contamination with exocrine tissue since the 
presence of musearlnie receptors on acini is weil 
known. 
2. 4. Binding experiments 
After the islets were isolated, they were washed 
in ice-cold Hanks solution using centrifugation. 
Fifty islets were incubated in 0.3 ml Krebs-Ringer 
bicarbonate buffer plus 20 mM HEPES (KRBH) 
buffer, pH 7.4, containing 5 mg/ml bovine al-
bumin, 1 mg/ml bacitracin and 0.1 mg/ml SBTI; 
5 nM eH]NMS, with or without 100 ~tM un-
labelled atropine, was then added. Binding experi-
ments were performed in the presence of 16.7 mM 
glucose since elevated binding has been shown 
clearly with long-term high glucose concentrations 
or hyperglycemia (Östenson and Grill, 1985; 1987). 
The incubation was terminated by cooling the 
samples ( 4 ° C), and the incubation mixtures were 
then filtered through glass microfibre filters 
(Whatman GF /C, U.K.) for 2 s under reduced 
pressure. The filters were then washed twice with 
0.2 m1 ice-cold KRBH-buffer, which took less 
than 15 s. The dissociation experiment ai 4 ° C 
illustrated in fig. 1 (dotted line) showed that no 
major dissociation was to be expected during the 
washing procedure. The filters were suspended in 
the scintillation cocktail (toluene, ethylene glycol 
monomethylether and 2,5-diphenyloxazole), 
shaken vigorously and counted in a ß-scintillation 
spectrometer after luminescence bad disappeared. 
To establish the apparent receptor affinity (dis-
sociation constant, Kd) the competitive inhibition 
of specific [3 H]NMS binding by various con-
centrations of unlabelled antagonists was analyzed. 
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This was done by fitting plots for bound drugs 
versus free drugs by means of a non-linear Ieast-
squares computerprogram that analyzed the data 
in terms of one non-saturable and one or two 
saturable components (Dixon, 1974). 
2.5. Insulin and glucagon secretion 
To measure insulin secretion, five islets were 
incubated for 60 min at 37 ° C in the aforemen-
tioned KRBH buffer after having been primed for 
60 min with 16.7 mM glucose. Insulin and gluca-
gon released into the medium by the islets was 
assayed with radioimmunoassay kits using rat in-
sulin or glucagon as a standard. Each compound 
had been checked for non-interference with the 
insulin and glucagon radioimmunoassays. For 
statistical evaluation of whole curves, multiple 
comparisons of means were carried out by two-way 
analysis of variance (F-test). Dunnett's test was 
used thereafter if several conditions were to be 
compared to the control experiments. EC50 s of 
biologic effects were determined by means of the 
RS/1 statistics pack (BBN Software Products 
Corp.). 
2.6. Proteindetermination 
The protein content was measured in extra 
batches within each binding experiment. The pro-
tein content of the solubilized pancreatic islets 
(solubilized with 0.1 N NaOH) was measured 
using bovine serum albumin as a standard (Brad-
ford, 1976). 
3. Results 
3.1. Timecourse of [ 3H]NMS binding 
The binding of 5 nM [3H]NMS to isolated rat 
islets at 37 ° C was half maximal after 30 min and 
maximal binding occurred at 60 min ( fig. 1 ). The 
velocity of binding was much lower than that 
shown earlier by Grill and Östenson (1983) and by 
Malaisse et al. (1985). At 60 min, maximal binding 
was 1.29% of added radioactivity per 10 11-g islet 
protein. N on-specific binding ( determined in the 
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Fig. 1. Timecourse of (3H]NMS binding to isolated rat islets 
of Langerhans. Fifty islets were incubated in 0.3 ml KRH-al-
bumin buffer for 90 min at 37°C with 5 nM [3H]NMS in the 
absence (e) and presence ( o) of 0.1 mM atropine. After 
washing at 30 min some batch-incubated islets were ro-in-
cubated in radioactivity-free medium at 4 ° C in order to 
determine the dissociation velocity in the absence of ligands 
<•>· The results are expressed as % bound per 10 p.g islet 
protein. Each value represents the mean ± S.E. of three to four 
separate experiments. 
presence of 100 p.M atropine) ranged from 0.10 to 
0.2690 of added radioactivity per 10 p.g islet pro-
tein. All subsequent binding studies were therefore 
carried out for 60 min. At 30 min, dissociation of 
TABLE 1 
Effects of muscarinic receptor agonists and various antagonists 
on receptor binding, insulin release and glucagon release. Ac-
tivities were calculated as dissociation constants of high- and 
low-affinity binding (Kd1 and Kd2 ) and as half maximally 
regulated insulin or glucagon release (EC50 ) of high-affinity 
effect. The vaJues were calculated from data shown in figs. 2-7. 
• NS vs. pirenzepine (P < 0.05); b NS vs. atropine (P > 0.05). 
Number of experiments in parentheses. 
Compound 
Agonist 
APE 
Antagonists 
Atropine 
SiHC 
Pirenzepine 
Methoctramine 
Kdt 
(nM) 
8.06 (4) 
±1.04 
8.46 (4) 
± 1.13 
55.6 (4) 
±3.89 
1340 (4) 
±211 
1280 (4) 8 
±154 
Kd2 
(nM) 
5840 (4) 
±631 
463 (4) 
±54 
1940 (4) 
±128 
9100 (4) 
±641 
55000 (4) 
±6100 
EC50 (nM) 
Insulin Glucagon 
secretion secretion 
3.23 (12) 2.34 (12) 
±0.25 ±0.31 
9.18 (3) 11.3 (3) 
±0.94 ±0.99 
6.32 (3) b 364 (3) 
±1.03 ±27.3 
432 (4) 1510 (4) 
±22.6 ±213 
2130 (3) 2380 (3) 8 
±198 ±468 
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Fig. 2. Inhibition by the agonist, APE, of [-' H]NMS binding to 
isolated rat islets of Langerhans. Fifty islets were incubated in 
0.3 ml KRH-albumin buffer for 60 min at 37 o C with 5 nM 
( 3 H]NMS and increasing concentrations of agonist. The resul ts 
are expressed as % bound per 10 p.g islet protein. Each value 
represents the mean ± S.E. of four separate experiments. 
labeled Iigand at 4 ° C was slow, i.e. the half life 
was more than 60 min. 
3.2. Muscarinic receptor agonist, APE 
APE inhibited [ 3 H]NMS binding in a con-
centration-related manner (fig. 2). Inhibition was 
essentially complete over four orders of magnitude 
(1-10000 nM). Binding analysis of the competi-
tion-inhibition curve revealed more than a single 
binding site with a Kd1 of 8.06 nM and Kd2 of 
5840 nM (table 1) and a Capacity of Bmaxi = 36.8 
and Bmax2 = 91.9 fmol/10 p.g islet protein. 
In rat pancreatic islets, glucose alone (absence 
of muscarinic receptor agonist) increased insulin 
release (fig. 3). APE increased insulin release in a 
dose-dependent biphasic manner that was inde-
pendent of the glucose concentration (3.0 mM = 
substimulatory and 16.7 mM = stimulatory). Glu-
1200 
-; 1000 
! 
.I 
., 
800 
' j. 
j 800 ; 
• 
. j_i 
r 
I . • • • 
• • • i*/ ~ ~._.~ _ . ._._.-
·-· i-11__.... 
i 
• 400 I 
J 
200 
0 
APE Cll) 
Fig. 3. Stimulation of insulin release by the musearlnie receptor 
agonist, APE. Five islets were incubated in the same buffer 
with various APE concentrations for 60 min at 37 ° C in the 
presence of non-stimulatory glucose (3.0 mM ( 0 )) or stimula-
tory glucose (16.7 mM <•»· The results are expressed as f.LU 
insulin secreted per Cive islets over 60 min. Each value repre-
sents the mean ± S.E. of 12 separate experiments (F = 5.12, 
P < 0.01 at 16.7 mM glucose; F= 4.46, P < 0.01 at 3 mM 
glucose; * P < 0.05 and • • P < 0.01 both vs. absence of APE). 
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Fig. 4. Stimulation of glucagon release by the musearlnie 
receptor agonist, APE. Five islets were incubated in the same 
buffer with various APE concentrations for 60 min at 37 o C in 
the presence of non-stimulatory glucose (3.0 mM, <>) or stimu-
latory glucose (16.7 mM, •>· The results are expressed as pg 
glucagon secreted per five islets over 60 min. Each value 
represents the mean ± S.E. of 12 separate experiments (F"" 4.93, 
P < 0.02 at 3 mM glucose; F= 4.31, P < 0.01 at 16.7 mM 
glucose; • P < 0.05 and • • P < 0.02 both vs. absence of APE). 
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~··· Fig. 5. Inhibition of [3 H]NMS binding to isolated rat islets of 
Langerhans by antagonists: 50 islets were incubated in 0.3 ml 
KRH-albumin buffer for 90 min at 37 ° C with 5 nM ( 3 H}NMS 
and increasing concentrations of antagonists. The antagonists 
were: {e) atropine, <•> SiHC, (o) pirenzepine, (D) methoctra-
mine. The results are expressed as % bound per 10 p.g islet 
protein. Each value represents the mean ± S.E. of four separate 
experiments. 
cose alone (absence of muscarinic receptor agonist) 
decreased glucagon release (fig. 4). APE increased 
glucagon release in a dose-dependent biphasic 
mannerat both 3.0 and 16.7 mM glucose. 
3.3. Muscarinic receptor antagonists 
The concentration of unlabelled atropine caus-
ing half maximal inhibition of [3 H]NMS binding 
was ca. 30 nM (IC50 ) (fig. 5). Binding analysis of 
the competition-inhibition curves generated with 
unlabelled antagonists revealed more than a single 
binding site with Hili coefficients of less than 0.6 
in all cases. For atropine, e.g. Kd1 was 8.46 ± 1.13 
and Kd2 was 463 ±54 nM, respectively. The rank 
order for inhibition of antagonist high-affinity 
binding was atropine > SiHC > pirenzepine = 
methoctramine (table 1). 
When islets were stimulated by 10 p.M APE in 
the presence of 16.7 mM glucose, muscarinic re-
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ceptor antagonists inhibited insulin release (fig. 6). 
The rank order of potency was atropine = SiHC > 
pirenzepine > methoctramine (table 1). No 
antagonist lowered insulin release below the val-
ues obtained with glu~ose alone (fig. 6), and no 
antagonist antagonized the effect of glucose alone 
(data not shown). 
In the presence of 3 mM glucose plus 10 p.M 
APE, muscarinic receptor antagonists inhibited 
glucagon release (fig. 7). The rank order of potency 
was atropine > SiHC > pirenzepine = methoctra-
mine (table 1). Atropine, but not other antagonists 
lowered glucagon release below values obtained 
wi th glucose alone ( fig. 7). 
4. Discussion 
4.1. Muscarinic receptor agonist 
Our data clearly show that muscarinic binding 
sites are present on rat pancreatic islets. APE 
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Fig. 6. Inhibition of APE-stimulated insulin release by 
musearlnie receptor antagonists. Five islets were ineubated 
with inereasing eoneentrations of antagonists in the presence 
of 16.7 mM glucoseplus 10 llM APE for 60 min at 37° C. The 
antagonists were: (e) atropine, <•> SiHC, (o) pirenzepine, (D) 
methoctramine. The results are expressed as maximal % secreted 
insulin. Each value represents the mean ± S.E. of three separate 
experiments (* P < 0.05, * * P < 0.02, • • • P < 0.001 vs. ab-
senee of antagonists). 
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Fig. 7. Inhibition of APE-stimulated glueagon release by 
musearinic receptor antagonists. Five islets were incubated 
with increasing concentrations of antagonists in the presence 
of 3.0 mM glueose plus 10 I'M APE for 60 min at 37 ° C. The 
antagonists were: (e) atropine, <•> SiHC, (o) pirenzepine, (D) 
methoctramine. The results are expressed as maximal % seereted 
glucagon. Eaeh value represents the mean ± S.E. of three sep-
arate experiments ( • P < 0.05, • • P < 0.01, • * • P < 0.001 vs. 
absenee of antagonists). 
which is selective for muscanruc over nicotinic 
receptors inhibits [3H]NMS binding and stimu-
lates both insulin and glucagon release at similar 
concentrations in a biphasic, dose-dependent 
manner. 
4.2. Muscarinic receptor antagonists 
Since no agonists selective for muscarinic re-
ceptor subtypes are available, antagonist were now 
used to characterize the muscarinic receptor sub-
type in rat pancreatic islets. There was a clear 
rank order of affinity: the highest affinity was 
found for the compound, SiHC, which exhibits a 
similar affinity for M1 and for M 3 receptors 
(Lambrecht et al., 1987; Waelbroeck et al., in 
press). The low affinity of pirenzepine indicates 
that the M1 subtype is not important and the low 
affinity of methoctramine indicates that M2 recep-
tor subtypes arenot predominant in rat pancreatic 
islets. The M 3 receptor subtype also appears tobe 
that most involved in A-cells. This receptor sub-
type had orlginally been named M4 • Functional 
data reported by Henquin and Nenquin (1988) 
make it likely that this subtype is involved in islets 
effects. 
4.3. lnitiating or modulating effect of a museartnie 
receptor agonist? 
Ambient glucose stimulates insulin secretion 
and inhibits glucagon secretion (Verspohl and 
Ammon, 1987). The musearlnie receptor agonist, 
APE, both initiates and modulates insulin release. 
The fact that, in cantrast to Herrnans et al. (1986), 
we were able to show an initiating (absence of 
stimulatory glucose) insulinotropic effect of a 
musearlnie receptor agonist may have been due to 
species differences (mouse) or to the fact that our 
islets were prlmed by an 1-h preincubation in the 
presence of 16.7 mM glucose or been the result of 
using a highly specific agonist in contrast to other 
groups. 
The musearlnie receptor agonist, APE, is able 
to modulate the glucose-mediated inhibition of 
glucagon release. Our data confirm those of 
Östensen and Grill (1985) by showing that 
musearlnie receptor antagonists inhibit the gluca-
gon release stimulated by cholinergic substances. 
The receptor subtype population cannot be de-
cided from binding studies alone since rat pan-
creatie islets are a heterogenaus cell population 
which may obscure a receptor subtype on a cell 
type which is only present in low amounts. The 
functional data nevertheless indicate, first that the 
measured binding sites are related to the B and A 
cells of rat pancreatic islets and, second, that the 
musearlnie receptor agonist bad an insulinotropic 
and glucagonotropic effect independent of the glu-
cose concentration used. 
4.4. Extrapolation of the in vitro situation 
These in vitro data will need further evaluation 
from in vivo experiments since atropine and possi-
bly other antagonists have been claimed based on 
the in vivo experiments, to behave differently by 
not being selective. Atropine and pirenzepine not 
only do antagonize musearlnie effects but they 
also antagonize secretin and cholecystokinin-
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mediated effects (Otsuki et al., 1987; You and 
Chey, 1988). 
Taken together, our data are consistent with the 
opinion that rat pancreatic islets contain M3 
musearlnie subtypes as also does the exocrine 
pancreas (Louie and Owyang, 1985; Dehaye et al., 
1983). ldentifying selective M 3 agonist interacting 
with the endocrlne panereas but hopefully not 
with other glands would provide a valuable tool 
for the development of new insulinotropic drugs. 
In conciusion, the binding and functional data 
indicate the predominant presence of an M 3 re-
ceptor subtype in the rat pancreatic islets. 
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